Konstanze Hörtnagel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Konstanze Hörtnagel has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Saskia Biskup
Zentrum für Humangenetik, Tübingen, Germany
2 shared publications - Alexander Pepler
Center for Genomics and Transcriptomics and Praxis für Humangenetik Tübingen, Tübingen, Germany
1 shared publication - Alexey Larionov
University of Cambridge
1 shared publication - Bertold Schrank
DKD Helios Klinik Wiesbaden
1 shared publication - Christian Vollmar
Epilepsy Center, Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
1 shared publication - Claudia B. Catarino
Friedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, Ludwig-Maximilian University (LMU) Munich, Munich, Germany
1 shared publication
Latest Publications
- 1 October 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (10) , 2238-2241.e6
Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause Rare Sweat Duct Proliferations and Irregular Elastin Aggregations
- 1 October 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (10) , 2238-2241.e6
Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause Rare Sweat Duct Proliferations and Irregular Elastin Aggregations
- 19 December 2017
- Published by Springer Nature in Journal of Neurology
- Vol. 265 (2) , 388-393
Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment
Cerebrotendinous xanthomatosis (CTX, MIM 213700) is a rare autosomal recessive lipid storage disorder caused by CYP27A1 mutations. Treatment with chenodeoxycholic acid (CDCA) may slow the progression of the disease and reverse some symptoms in a proportion of patients. In a non-consanguineous Caucasian family, two siblings with CTX were evaluated before treatment and prospectively followed-up every 6 months after starting CDCA therapy, using systematic clinical examination, neuropsychological tests, laboratory tests, electroencephalography (EEG) and brain MRI, diffusion tensor imaging (DTI) and tractography. A 30-year-old patient and her 27-year-old brother were referred for progressive spastic paraparesis. Both had epilepsy, learning difficulties, chronic diarrhoea and juvenile-onset cataracts. CTX was diagnosed by increased cholestanol levels and compound heterozygosity for CYP27A1 mutations. Therapy with CDCA led to resolution of chronic diarrhoea, normalisation of serum cholestanol and EEG, and a progressive improvement in gait, cognition and seizure control. Before treatment, conventional brain MRI showed no CTX-related abnormalities for the proband and no cerebellar abnormalities for the brother, while DTI showed reduced fractional anisotropy (FA) and tract-density in the cerebellum and widespread cerebral reductions of FA in both patients, compared to a group of 35 healthy controls. Repeated DTI after starting therapy showed progressive increases of cerebellar tract density and of cerebral FA. In patients with CTX, therapy with CDCA may lead to significant clinical improvement, with normalisation of biochemical and electrophysiological biomarkers. DTI and tractography may detect changes when the conventional MRI is unremarkable and may provide potential neuroimaging biomarkers for monitoring treatment response in CTX, while the conventional MRI remains unchanged.
- 19 December 2017
- Published by Springer Nature in Journal of Neurology
- Vol. 265 (2) , 388-393
Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment
Cerebrotendinous xanthomatosis (CTX, MIM 213700) is a rare autosomal recessive lipid storage disorder caused by CYP27A1 mutations. Treatment with chenodeoxycholic acid (CDCA) may slow the progression of the disease and reverse some symptoms in a proportion of patients. In a non-consanguineous Caucasian family, two siblings with CTX were evaluated before treatment and prospectively followed-up every 6 months after starting CDCA therapy, using systematic clinical examination, neuropsychological tests, laboratory tests, electroencephalography (EEG) and brain MRI, diffusion tensor imaging (DTI) and tractography. A 30-year-old patient and her 27-year-old brother were referred for progressive spastic paraparesis. Both had epilepsy, learning difficulties, chronic diarrhoea and juvenile-onset cataracts. CTX was diagnosed by increased cholestanol levels and compound heterozygosity for CYP27A1 mutations. Therapy with CDCA led to resolution of chronic diarrhoea, normalisation of serum cholestanol and EEG, and a progressive improvement in gait, cognition and seizure control. Before treatment, conventional brain MRI showed no CTX-related abnormalities for the proband and no cerebellar abnormalities for the brother, while DTI showed reduced fractional anisotropy (FA) and tract-density in the cerebellum and widespread cerebral reductions of FA in both patients, compared to a group of 35 healthy controls. Repeated DTI after starting therapy showed progressive increases of cerebellar tract density and of cerebral FA. In patients with CTX, therapy with CDCA may lead to significant clinical improvement, with normalisation of biochemical and electrophysiological biomarkers. DTI and tractography may detect changes when the conventional MRI is unremarkable and may provide potential neuroimaging biomarkers for monitoring treatment response in CTX, while the conventional MRI remains unchanged.
- 30 June 2017
- Published by Georg Thieme Verlag KG in Klinische Neurophysiologie
- Vol. 48 (02) , 102-106
Dropped Head Syndrom als Folge einer behandelbaren metabolischen Myopathie
Wir berichten über den ungewöhnlichen Fall einer metabolischen Myopathie, die sich mit einem Dropped Head Syndrom (DHS) mit myographischen und bildgebenden Veränderungen vereinbar mit einer fokalen inflammatorischen Myopathie erstmanifestierte. Der Fall zeigt, dass die gezielte Biopsie auch schwerer zugänglicher Muskeln entscheidend sein kann zur korrekten Diagnose.
- 30 June 2017
- Published by Georg Thieme Verlag KG in Klinische Neurophysiologie
- Vol. 48 (02) , 102-106
Dropped Head Syndrom als Folge einer behandelbaren metabolischen Myopathie
Wir berichten über den ungewöhnlichen Fall einer metabolischen Myopathie, die sich mit einem Dropped Head Syndrom (DHS) mit myographischen und bildgebenden Veränderungen vereinbar mit einer fokalen inflammatorischen Myopathie erstmanifestierte. Der Fall zeigt, dass die gezielte Biopsie auch schwerer zugänglicher Muskeln entscheidend sein kann zur korrekten Diagnose.